News | October 06, 2009

Direct Flow Medical Presents 12-Month Data on Percutaneous Aortic Valve System

October 6, 2009 – Direct Flow Medical Inc. released its One-year data from the initial clinical trial for its transcatheter prosthetic aortic valve during the recent Transcatheter Cardiovascular Therapeutics (TCT) 2009 meeting .

Professor Joachim Schofer from Hamburg, Germany presented the prospective, nonrandomized data from the European Feasibility and Safety Trial. A total of 31 patients were enrolled at two centers in this first in human clinical trial. The one-year risk adjusted survival rate in this study was 72 percent, which is significantly better than the predicted survival of this patient population if they were treated by conventional surgery or medical management. The survival rate is comparable to survival rates reported with the first generation transcatheter aortic valve interventional (TAVI) devices now commercially available in Europe.

The patients in the study also benefited from a significant improvement in quality of life as measured by NYHA functional class. Most patients had an improvement of at least two functional classes. “The improvement in functional class appears to be due to the low incidence of perivalvular leak, and the unique ability of the Direct Flow device to seal to the native annulus,” said Dr. Hendrik Treede, a cardiothoracic surgeon and study coinvestigator in Hamburg.

Also at the TCT meeting, professor Schofer reported two-year data on the first patient treated with the Direct Flow Medical 22 Fr. Percutaneous Aortic Valve (PAV) System. Before treatment, the 81-year-old patient was suffering from critical aortic stenosis with an effective orifice area of 0.56 cm2 and was NYHA Class III. Because of severe comorbidities, the patient was not a surgical candidate. At the two year follow-up the excellent acute clinical result was maintained; the patient remains NYHA Class I with a mean pressure gradient of 10 mmHg, an effective orifice area of 1.98 cm2 and he maintains an active life style. An additional six patients implanted with the Direct Flow Medical device are surviving beyond 18 months post treatment despite having an average age of 82 and a logistic EuroScore of greater than 27 at implant.

“We are pleased to report the positive data, results and clinical outcomes demonstrated in our patients at one-year post implant and beyond, particularly in the areas of stable post procedure gradients and improved NYHA functional class,” said professor Schofer. “We anticipate that with the development of the new 18 Fr. device from Direct Flow Medical we will be able to accelerate patient enrollment and increase our clinical experience with this unique, next generation device.”

For more information: www.directflowmedical.com

Related Content

Videos | Heart Valve Technology | July 10, 2018
Ori Ben-Yehuda, M.D., executive director of the Cardiovascular Research Foundation Clinical Trial Center, discusses t
Videos | Heart Valve Technology | July 05, 2018
Rebecca Hahn, M.D., professor of medicine and director of interventional echocardiography, Columbia University Medica
Henry Ford Hospital First in Michigan to Perform Cardioband Mitral Valve Procedure

An angiography image showing the catheter-based implantation of the Cardioband annuloplasty ring using corkscrew shaped anchors.

News | Heart Valve Technology | June 13, 2018
Henry Ford Hospital is one of 17 U.S. trial sites using a catheter-based procedure approved in Europe to repair a leaky...
Abbott Portico transcatheter aortic valve replacement (TAVR) performed well PORTICO I real-world study. #EuroPCR
News | Heart Valve Technology | June 01, 2018
June 1, 2018 –  Use of the Abbott Portico transcatheter aortic valve replacement (TAVR) therapy was associated with e
Tendyne Transcatheter Mitral Valve Replacement Device Demonstrates Positive 30-Day Outcomes
News | Heart Valve Technology | May 25, 2018
Abbott announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter...
A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital.

A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital. 

Feature | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study finds patients who stay in the hospital for more than 72 hours when undergoing trans-femor
The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.  #SCAI, #SCAI2018

The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.

News | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study examines the effectiveness of 3-D printing technology and computer modeling to predict par
First-Ever Risk Tool Helps Predict TAVR Readmission Rates in 2018 SCAI late-breaking study. #SCAI, #SCAI2018
News | Heart Valve Technology | May 11, 2018
A new study looked at the effectiveness of a novel risk tool to predict 30-day readmission rates in patients undergoing...
Medtronic Shares Two-Year Harmony Transcatheter Pulmonary Valve Results at SCAI 2018. #SCAI, #SCAI2018
News | Heart Valve Technology | May 11, 2018
Medtronic plc announced two-year outcomes for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
Colibri Heart Valve Continues Enrollment in TAVI Early Feasibility Study
News | Heart Valve Technology | May 07, 2018
Colibri Heart Valve LLC announced the Colibri transcatheter aortic valve implantation (TAVI) System has been used on an...
Overlay Init